Quantitative Macrocyclic Peptide Discovery and Engineering: Precision at Scale

Our proprietary platform is designed to accelerate the discovery of genetically encoded macrocyclic peptides with high affinity and selectivity against challenging therapeutic targets.

We integrate yeast surface display with quantitative flow cytometry to analyze billions of macrocyclic peptide variants in parallel. This approach is rapid, fully trackable, and eliminates the need for upfront chemical synthesis.

Unlike traditional methods, our technology enables real-time monitoring and ranking of binding affinities, providing full control over the selection process and delivering high-quality results faster (’failing early to succeed faster’)